Researchers found that a new drug called XPHOZAH (tenapanor) can effectively lower high phosphate levels in adults with chronic kidney disease (CKD) who are on dialysis. This drug is particularly useful for patients who do not respond well to traditional phosphate binders, offering a new approach to managing this common issue. By taking one tablet twice daily, patients may experience better control of their serum phosphorus levels, which is crucial for overall health, particularly for those dealing with CKD.

This discovery is significant for anyone looking to age well, especially those with kidney issues. High phosphate levels can lead to serious health complications, including cardiovascular problems and bone disease. In studies, XPHOZAH demonstrated the ability to reduce serum phosphate without affecting other important electrolytes, which means it can help maintain a healthier balance in the body. For patients with CKD on dialysis, managing phosphate levels is essential, as nearly all of them experience hyperphosphatemia, or elevated phosphate levels.

The research presented at the National Kidney Foundation’s Spring Clinical Meetings is based on data from two clinical trials, which included a total of 330 patients. While the results are encouraging, they are from early-stage studies and should be viewed as promising but not yet conclusive for all patients. The most common side effect reported was diarrhea, which affected a significant portion of participants but was generally mild to moderate.

If you or someone you know is managing chronic kidney disease, discussing the potential benefits of XPHOZAH with a healthcare provider may be worthwhile, especially if phosphate levels are a concern. Always consider the full range of treatment options and potential side effects before making any changes to your health regimen.

Source: globenewswire.com